We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
MIRA

Price
1.22
Stock movement down
-0.01 (-0.81%)
Company name
MIRA Pharmaceuticals, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers - General
Market cap
23.26M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
69.44%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-08-27

DIVIDENDS

MIRA does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.28
Daily high1.28
Daily low1.20
Daily Volume85K
All-time high7.08
1y analyst estimate17.75
Beta1.79
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date3 Sep 2025

Downside potential

Loading...
Downside potential data
MIRAS&P500
Current price drop from All-time high-82.77%-3.04%
Highest price drop-92.34%-56.47%
Date of highest drop9 Jul 20249 Mar 2009
Avg drop from high-75.11%-11.04%
Avg time to new high118 days12 days
Max time to new high469 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
MIRA (MIRA Pharmaceuticals, Inc. Common Stock) company logo
Marketcap
23.26M
Marketcap category
Small-cap
Description
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Employees
0
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS